Finasteride Tablet, Film Coated
Product Images NDC 0904-6830

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 0904-6830). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1cafe01a 4316 439d Bc82 9e68b37cdb1a 00

Label for Finasteride 5 mg film-coated tablets by Major Pharmaceuticals. The packaging is Unit Dose with NDC 0904-6830-06 and contains 50 tablets. The label includes the proprietary and generic name, dosage strength, usage warnings, manufacturer and distributor information, and a barcode.*

FDA Label Image

Address.jpg (Address)

FDA Label Image

Address3.jpg (Address3)

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing the mean change from baseline in a measured variable over a four-year period for Finasteride 5 mg versus placebo. The graph depicts two lines with associated sample sizes at various time points, illustrating a greater reduction with Finasteride compared to placebo across the study duration.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled "Figure 2 Percent of Patients Having Surgery for BPH, Including TURP" comparing the percentage of patients undergoing surgery over time between Finasteride and placebo groups. The x-axis shows observation time in months (0 to 48), and the y-axis shows the percent of patients (0% to 15%). Finasteride group consistently shows a lower percentage of surgery compared to placebo across the observation period.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph showing mean percent change from baseline with standard error bars over a 4-year period for Finasteride 5 mg tablets compared to placebo. The graph tracks two groups, with placebo showing an increasing positive trend and Finasteride showing a decreasing negative trend across baseline, year 1, year 2, year 3, and year 4.*

FDA Label Image

Figure4.jpg (Figure4)

A line chart depicting the percent with event over years from randomization for four groups: Placebo, Finasteride, Doxazosin, and Combination. The x-axis represents years from 0 to 5.5, and the y-axis represents percent with event ranging from 0 to 25%. Placebo shows the highest trend, followed by Finasteride, Doxazosin, and Combination with the lowest percent with event over time.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of finasteride, showing its steroidal ring system and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.